Back to EveryPatent.com
United States Patent |
5,314,889
|
Boigegrain
,   et al.
|
May 24, 1994
|
Heterocyclic substituted 2-acylamino-5-thiazoles, their preparation and
pharmaceutical compositions containing them
Abstract
A 2-Acylaminothiazole of formula:
##STR1##
in which R.sub.1 is H, an alkyl or a substituted alkyl; R.sub.IV is a
cycloalkyl, an aromatic group such as phenyl or a heterocyclic group which
are unsubstituted or substituted; R.sub.V is a substituted alkyl, a
substituted carboxy such as an ester or an amide; or R.sub.IV and R.sub.V
together represent a phenoxyalkylene group which may be substituted on the
phenyl; and Z is a heterocyclic e.g. indolyl group; or a salt of compound
(I).
Inventors:
|
Boigegrain; Robert (Assas, FR);
Brodin; Roger (Montpellier, FR);
Gully; Danielle (Saubens, FR);
Molimard; Jean-Charles (Saint Gely Du Gesf, FR);
Olliero; Dominique (Montpellier, FR)
|
Assignee:
|
Elf Sanofi (Paris, FR)
|
Appl. No.:
|
889910 |
Filed:
|
May 29, 1992 |
Foreign Application Priority Data
Current U.S. Class: |
514/254.02; 514/307; 514/314; 514/326; 514/365; 514/366; 514/367; 514/369; 514/370; 514/371; 514/372; 514/374; 514/375; 514/376; 514/377; 514/378; 514/385; 544/116; 544/119; 544/120; 544/124; 544/128; 544/130; 544/133; 544/135; 544/137; 544/139; 544/140; 544/141; 544/142; 544/143; 544/145; 544/146; 544/147; 544/152; 544/153; 544/235; 544/353; 544/357; 544/360; 544/363; 544/364; 544/366; 544/367; 544/368; 544/369; 544/370; 544/371; 544/372; 544/373; 544/374; 544/375; 544/376; 544/379; 546/139; 546/144; 546/145; 546/167; 548/151; 548/195; 548/196 |
Intern'l Class: |
A61K 031/495; A61K 031/50; A61K 031/425; A61K 031/415; C07D 413/00; C07D 417/00; C07D 405/00; C07D 411/00; 360; 363; 364; 366-376; 379 |
Field of Search: |
544/120,124,128,116,119,130,133,135,137,139,140-143,145-147,152,153,235,353,357
548/151,182,185,190-196,197,152,195
546/139,144,145,167
514/252,253,307,314,326,365,367,366,369,370-372,374-378,385
|
References Cited
Foreign Patent Documents |
0208510 | Jan., 1987 | EP.
| |
0308885 | Dec., 1988 | EP.
| |
0348523 | Jan., 1990 | EP.
| |
0432040 | Jun., 1991 | EP.
| |
3705934 | Sep., 1988 | DE.
| |
Other References
Bras et al., Chem. Abst. 116-21039y (1991).
Nguyen Minh Thao et al, Chem. Abst. 112-115589x (1989).
Uhlendorf et al, Chem. Abst 110-231432y (1988).
Nguyen Minh Thao et al, Chem. Abst. 101-171158n (1984).
Bourdais, Chem. Abst. 78-136065t (1972).
|
Primary Examiner: Tsang; Cecilia
Attorney, Agent or Firm: Wegner, Cantor, Mueller & Player
Claims
We claim:
1. 2-Acylaminothiazole compound of the formula:
##STR110##
in which R.sub.1 is hydrogen;
R.sub.IV is (C.sub.3 -C.sub.7)cycloalkyl, (C.sub.1 -C.sub.4
)alkyl-substituted (C.sub.3 -C.sub.7)cycloalkyl, phenyl, or phenyl
substituted by one or more halogen, (C.sub.1 -C.sub.6)alkyl, (C.sub.1
-C.sub.3)alkoxy, (C.sub.1 -C.sub.3)thioalkoxy, nitro, or trifluoromethyl,
or R.sub.IV and R.sub.V, taken together, are:
##STR111##
in which u is an integer from 1 to 3, np is an integer from 0-3, Xp is
halogen, (C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkoxy, nitro or
trifluoromethyl, and Xp is the same or different when np is 2 or 3;
R.sub.V is --(CH.sub.2).sub.m --X in which m is an integer from 0 to 5 and
X is:
(i) halogen, hydroxyl, (C.sub.3 -C.sub.7)cycloalkyl, phenyl, or phenyl
substituted with halogen, (C.sub.1 -C.sub.3)alkyl, (C.sub.1
-C.sub.3)alkoxy, nitro, amino, hydroxyl or trifluoromethyl;
(ii) --COOH; --COOX.sub.1 ; --O--COX.sub.1 ; --SCOX.sub.1 ;
##STR112##
wherein q is an integer from 0 to 2;
##STR113##
wherein X.sub.3 is hydrogen or (C.sub.1 -C.sub.3)alkyl;
##STR114##
wherein W is O or S;
##STR115##
wherein s is an integer from 2 to 4; in which X.sub.1 is (C.sub.1
-C.sub.3)alkyl; phenyl; phenyl substituted by one or more halogen,
(C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkoxy, nitro, amino, hydroxyl,
or trifluoromethyl; or adamantyl;
(iii) --NX.sub.1 X.sub.2 or --CONX.sub.1 X.sub.2 in which X.sub.1 is
hydrogen, (C.sub.1 -C.sub.3)alkyl, phenyl, or phenyl substituted by one or
more halogen, (C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkoxy, nitro,
amino, hydroxy or trifluoromethyl, and X.sub.2 is hydrogen or (C.sub.1
-C.sub.3)alkyl; or alternatively, X.sub.1 and X.sub.2 constitute, with the
nitrogen atom to which they are attached, pyrrolidino or pyrrolidino
substituted by oxo, hydroxyl, --O--COR in which R is (C.sub.1
-C.sub.5)alkyl, (--OCOOX.sub.1), as defined above, or (--OCONX.sub.1
X.sub.2) as defined above; or alternatively,
R.sub.V is (C.sub.1 -C.sub.5)alkoxy, hydroxyl, pyrrolidino, piperidino,
pyrrolidino substituted by oxo or hydroxyl, piperidino substituted by oxo
or hydroxyl, piperazinyl, or piperazinyl N-substituted by --COOAlk in
which Alk is (C.sub.1 -C.sub.5)alkyl; a carboxylic acid group; --NX.sub.2
X.sub.4 in which X.sub.4 is hydrogen or --(CH.sub.2).sub.1 --X.sub.5
wherein t is an integer from 2 to 4 and X.sub.5 is --OH, --O--CO--R.sub.2,
NHCOR.sub.2, or
##STR116##
in which R.sub.2 is (C.sub.1 -C.sub.6)alkyl; or --NR.sub.2 R.sub.3 wherein
R.sub.2 and R.sub.3 are independently H, (C.sub.1 -C.sub.6)alkyl, phenyl,
phenyl substituted by one or more halogen, (C.sub.1 -C.sub.3)alkyl, or
(C.sub.1 -C.sub.3)alkoxy, or R.sub.2 and R.sub.3 constitute, with the
nitrogen atom to which they are attached, pyrrolidino, piperidino,
pyrrolidino substituted by oxo or hydroxyl, piperidino substituted by oxo
or hydroxyl, piperazinyl, or piperazinyl N-substituted by --COOAlk in
which Alk is (C.sub.1 -C.sub.5)alkyl; and
Z is indolyl, indolyl substituted by one or more halogen, (C.sub.1
-C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkoxy, benzyloxy, nitro, amino or
trifluoromethyl, indoyl N-substituted by (C.sub.1 -C.sub.4)alkyl, or
carboxyalkylene-Z.sub.4 --COOR.sub.10 in which Z.sub.4 is (C.sub.1
-C.sub.4)alkylene and R.sub.10 is hydrogen, benzyl, or (C.sub.1
-C.sub.6)alkyl, or indolyl substituted by one or more halogen, (C.sub.1
-C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkoxy, benzyloxy, nitro, amino, or
trifluoromethyl and N-substituted by (C.sub.1 -C.sub.4)alkyl or
carboxyalkylene-Z.sub.4 --COOR.sub.10 is which Z.sub.4 is (C.sub.1
-C.sub.4)alkylene and R.sub.10 is hydrogen, benzyl, or (C.sub.1
-C.sub.6)alkyl;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, in which Z is indolyl or indolyl
N-substituted by (C.sub.1 -C.sub.4)alkyl, carboxyalkylene-Z.sub.4
--COOR.sub.10 in which Z.sub.4 is (C.sub.1 -C.sub.4)alkylene and R.sub.10
is hydrogen, benzyl, or (C.sub.1 -C.sub.6)alkyl.
3. The compound according to claim 1, in which R.sub.1 is H, Z is indoyl or
indolyl N-substituted by (C.sub.1 -C.sub.4)alkyl, carboxyalkylene-Z.sub.4
--COOR.sub.10 in which Z.sub.4 is (C.sub.1 -C.sub.4)alkylene and R.sub.10
is hydrogen, benzyl, or (C.sub.1 -C.sub.6)alkyl, and R.sub.IV is phenyl.
4. The compound according to claim 1, in which R.sub.IV is phenyl
substituted by, independently, one or more fluorine or chlorine.
5. The compound according to claim 1, in which R.sub.V is
--(CH.sub.2).sub.m --X wherein X is bromine.
6. A pharmaceutical composition useful as a cholecystokinin antagonist,
comprising a pharmaceutically effective amount of at least one compound
according to claim 1 and at least one pharmaceutically acceptable
excipient.
7. A pharmaceutical composition useful as a gastrin antagonist, comprising
a pharmaceutically effective amount of at least one compound according to
claim 1 and at least one pharmaceutically acceptable excipient.
8. A pharmaceutical composition for the treatment of physiological
disorders resulting from a hypersecretion of cholecystokinin or from a
dysregulation of hormonal systems in which cholecystokinin is involved,
comprising a pharmaceutically effective amount of at least one compound
according to claim 1 and at least one pharmaceutically acceptable
excipient.
9. A pharmaceutical composition for the treatment of physiological
disorders resulting from a hypersecretion of gastrin or from a
dysregulation of hormonal systems in which gastrin is involved, comprising
a pharmaceutically effective amount of at least one compound according to
claim 1 and at least one pharmaceutically acceptable excipient.
10. A pharmaceutical composition useful for the treatment of intestinal
dyskinesia, pancreatitis, regulation of appetite, or treatment of pain,
comprising a pharmaceutically effective amount of at least one compound
according to claim 1 and at least one pharmaceutically acceptable
excipient.
11. A pharmaceutical composition useful for the treatment or prophylaxis of
gastric ulcers, Zollinger-Ellison Syndrome, or hyperplasia of the G-cells
of the antrum, comprising a pharmaceutically effective amount of at least
one compound according to claim 1 and at least one pharmaceutically
acceptable excipient.
Description
The present invention relates to heterocyclic derivatives which interact
with the cholecystokinin and gastrin receptor.
Cholecystokinin (CCK) is a polypeptide hormone which occurs in vivo in
several forms containing 8 to 39 amino acids. It possesses many
physiological activities with respect to the bile ducts, the
gastrointestinal tract and on the central and peripheral nervous systems,
and reference may be made to the article by J. E. Morley in Life Sciences,
1982, 30, p. 479-493 which presents a detailed review of its properties.
Two different populations of CCK receptors have been detected by means of
specific antagonists; those of the A type which are present in particular
in the pancreas, in the gall bladder and in certain zones of the central
nervous system, while those of the B type occur mainly in the central
nervous system.
Gastrin is a polypeptide hormone which acts in particular on the acidic
secretion of the stomach; its 5 C-terminal amino acids are identical to
those of CCK.
Gastrin and/or CCK-antagonising compounds have already been described, in
particular proglumide, p-chlorobenzoyl-L-tryptophan, or more recently,
substituted benzodiazepines which are specific antagonists either of the
CCK A receptors, such as
3S(-)-N-2-[l-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-
2-indolecarboxamide (J. Med. Chem., 1988, 31, 2235-46), or of the CCK B
receptors, such as
3R(+)-N-[1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-N'
-[3-methylphenyl]urea (Eur. J. Pharmacology, 1989, 162, 273-280).
Thiazole CCK-antagonists are described in EP-A-0432 040,
Moreover, substituted thiazoles of formula:
##STR2##
in which A.sub.1 represents a 2,4-dimethoxyphenyl; a
2,3,4-tri-methoxyphenyl or a heterocyclic group such as a
3,4-di-hydro-7-methoxy-2,2,8-trimethylbenzopyran-1-2H-6-yl or a
3,4-dihydro-7-methoxy-2,2-dimethylbenzopyran-1-yl-2H-6-yl are described in
Indian J. Chem., Sec. B, 1988, 27 (B) 7, 629-32 as possessing bactericidal
or fungicidal properties.
Other substituted thiazoles of formula:
##STR3##
in which B.sub.1 represents hydrogen or a bromine atom are described in
Chem. Pharm. Bull., 1977, 25 (9), 2292-9 as possessing anti-inflammatory
properties.
Other substituted thiazoles of formula:
##STR4##
possess immunostimulant and anti-inflammatory properties and are described
in Arch. Immunol. Ther. Exp., 1978, 26 (1-6), 921-9.
Substituted 4-quinolinecarboxamides of formula:
##STR5##
are mentioned in Chem. Abst. 112 (13), 115 589 x as possessing
bactericidal and disinfectant properties.
The compounds according to the invention are heterocyclic substituted
2-aminothiazoles of formula (I):
##STR6##
in which R.sub.1 represents a hydrogen atom; a (C.sub.1 -C.sub.4) alkyl
group or a phenylalkylene group with a (C.sub.1 -C.sub.3) alkyl; an
aminoalkylene group of formula --Z.sub.1 -NR.sub.4 R.sub.5 in which
Z.sub.1 represents a (C.sub.2 -C.sub.4) alkylene and R.sub.4 and R.sub.5
represent, independently, H or a (C.sub.1 -C.sub.4) alkyl or form with the
nitrogen atom to which they are attached, a saturated heterocycle such as
morpholino, pyrrolidinyl, piperidino, piperazinyl or (C.sub.1 -C.sub.3)
4-alkylpiperazinyl; an optionally esterified carboxyalkylene group of
formula --Z.sub.2 --COOR.sub.6 in which Z.sub.2 represents a (C.sub.1
-C.sub.4) alkylene and R.sub.6 represents H or a (C.sub.1 -C.sub.6) alkyl;
a (C.sub.2 -C.sub.5) cyanoalkylene group; a carbamoylalkylene group of
formula --Z.sub.3 --CONR.sub.7 R.sub.8 in which Z.sub.3 represents a
(C.sub.1 -C.sub.4) alkylene and R.sub.7 and R.sub.8 represent,
independently, H or a (C.sub.1 -C.sub.4) alkyl, or with N, a heterocycle
such as NR.sub.4 R.sub.5 ; a (C.sub.2 -C.sub.6) hydroxyalkylene group, or
a (C.sub.1 -C.sub.10) alkoxyalkylene group; R.sub.IV represents a (C.sub.3
-C.sub.7) cycloalkyl group which is unsubstituted or substituted by one or
more (C.sub.1 -C.sub.4) alkyl groups; an aromatic group such as a phenyl
which is unsubstituted or which carries one or more substituents chosen
from halogen atoms, in particular chlorine or fluorine, (C.sub.1 -C.sub.8)
alkyl, and (C.sub.1 -C.sub.3) alkoxy and thioalkoxy groups, nitro and
trifluoromethyl groups or such as a heterocycle containing at least one
heteroatom chosen from O, S and N in particular a furyl, thienyl,
pyrrolyl, pyrazolyl, imidazolyl, pyridyl, pyrazinyl, oxazolyl and
thiazolyl, which are optionally substituted by a (C.sub.1 -C.sub.3) alkyl
group or a halogen atom or (C.sub.1 -C.sub.3) alkoxy or R.sub.IV and
R.sub.V, taken together, represent the group:
##STR7##
bound through the phenyl carbon in position 4 of the thiazolyl ring and in
which u equals 1 to 3, optionally carrying one or more (np) substituents
Xp, which are identical or different, chosen from halogen atoms, (C.sub.1
-C.sub.3) alkyl and alkoxy groups, nitro and trifluoromethyl groups, np
being equal to 0 to 3;
R.sub.V represents a group --(CH.sub.2).sub.m --X in which m is 0 to 5 and
X represents
a halogen atom, preferably a bromine atom, a hydroxyl, a (C.sub.3 -C.sub.7)
cycloalkyl, a phenyl which may be substituted by one of the groups chosen
from halogen atoms, (C.sub.1 -C.sub.3) alkyl or alkoxy groups, or nitro,
amino, hydroxyl or trifluoromethyl groups;
a group chosen from --COOH; --COOX.sub.1 ; --O--COX.sub.1 ; --SCOX.sub.1 ;
(O).sub.q -S-X.sub.1 with q =0. 1 or 2;
##STR8##
in which X.sub.1 represents a (C.sub.1 -C.sub.5) alkyl; a phenyl which
may be substituted by one or more groups chosen from halogen atoms,
(C.sub.1 -C.sub.3) alkyl or alkoxy groups or nitro, amino, hydroxyl or
trifluoromethyl groups; an adamantyl group;
a group chosen from --CONX.sub.1 X.sub.2 ; --NX.sub.1 X.sub.2 ; in which
X.sub.1 represents hydrogen, a (C.sub.1 -C.sub.3) alkyl or a phenyl which
is unsubstituted or substituted by one or more groups chosen from halogen
atoms, (C.sub.1 -C.sub.3) alkyl or alkoxy groups, or nitro, amino,
hydroxyl or trifluoromethyl groups and X.sub.2 represents a hydrogen atom,
a (C.sub.1 -C.sub.3) alkyl, or alternatively, X.sub.1 and X.sub.2
constitute, with the nitrogen atom to which they are attached, a
heterocycle chosen from pyrrolidine or piperidine which is unsubstituted
or substituted by an oxo group or by a hydroxyl group, the latter being
unsubstituted or substituted by an acyl, or by a --COOX.sub.1 or
--CONX.sub.1 X.sub.2 group;
or alternatively, R.sub.V represents a (C.sub.1 -C.sub.5) alkoxy; a
hydroxyl group; a cyclic amine with 5 or 6 members which is unsubstituted
or substituted by an oxo group or a hydroxyl group; a piperazinyl group
which is unsubstituted or N-substituted by a group --COOAlk in which Alk
represents a (C.sub.1 -C.sub.5) alkyl; a carboxylic acid group, a group
--NX.sub.2 X.sub.4 with X.sub.4 =H or X.sub.4 (CH.sub.2).sub.t --X.sub.5,
with t equal to 2, 3 or 4 and X. represents
##STR9##
in which R.sub.2 represents a (C.sub.1 -C.sub.6) alkyl; or a group
--NR.sub.2 R.sub.3 with R.sub.2 or R.sub.3 representing independently H,
(C.sub.1 -C.sub.6) alkyl, a phenyl group which is unsubstituted or
substituted by one or more substituents chosen from halogen atoms or a
(C.sub.1 -C.sub.3) alkyl group or a (C.sub.1 -C.sub.3) alkoxy group, or
R.sub.2 and R.sub.3 constitute, with the nitrogen atom to which they are
attached, a heterocycle with 5 or 6 members:
Z represents a heterocycle containing one or more heteroatoms chosen from
O, S and N, coupled to an aromatic nucleus which may also contain a
heteroatom chosen from O, S and N and which may be substituted by one or
more groups chosen from halogen atoms, (C.sub.1 -C.sub.3) alkyl and alkoxy
groups, or benzyloxy, nitro, amino and trifluoromethyl groups, it being
possible for the heteroatom N to be aromatic or in the form of --NH which
is unsubstituted or substituted by (C.sub.1 -C.sub.4) alkyl,
carboxyalkylene --Z.sub.4 --COOR.sub.10 in which Z.sub.4 represents
(C.sub.1 -C.sub.4) alkylene and R.sub.10 is H, benzyl or (C.sub.1
-C.sub.6) alkyl; carbamoylalkylene --Z.sub.5 --CONR.sub.11 R.sub.12 in
which Z.sub.5 represents (C.sub.1 -C.sub.4) alkylene and R.sub.11 and
R.sub.12 represent, independently, H, (C.sub.1 -C.sub.6) alkyl, or form
with N a saturated heterocycle such as morpholino or piperidino; acyl
COR.sub.13 with R.sub.13 representing (C.sub.1 -C.sub.4) alkyl or phenyl;
alkoxycarbonyl --COOR.sub.14 with R.sub.14 being tert-butyl or benzyl;
as well as the addition salts of these compounds with inorganic or organic
acids and bases; the pharmaceutically acceptable nontoxic salts are
prepared but other salts which may be used to isolate or purify the
compounds of formula (I) are also within the invention.
The alkyl, alkylene, alkoxy and thioalkoxy groups may be linear or
branched.
Z represents in particular benzothienyl, benzofuranyl, benzoxazolyl,
benzimidazolyl, benzothiazolyl, indolyl, isoindolyl, indolinyl,
isoindolinyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl,
cinnolinyl and [2,3-c]-thieno or [3,2-c]-pyridyl.
When Z represents an indolyl group of formula:
##STR10##
in which (Xi).sub.ni represents the optional substituents of the aromatic
nucleus, R.sub.9 may represent H; a (C.sub.1 -C.sub.4) alkyl group; an
optionally esterified carboxyalkylene group of formula --Z.sub.4
--COOR.sub.10 in which Z.sub.4 represents a (C.sub.1 -C.sub.4) alkylene
and R.sub.10 represents H, a benzyl or a (C.sub.1 -C.sub.6) alkyl; a
carbamoylalkylene group of formula --Z.sub.5 -CONR.sub.11 R.sub.12 in
which R.sub.11 and R.sub.12 represent, independently, H or a (C.sub.1
-C.sub.6) alkyl or form with N a saturated heterocycle chosen from
morpholino or piperidino and Z.sub.5 is a (C.sub.1 -C.sub.4) alkylene; an
acyl group of formula COR.sub.13 in which R.sub.13 represents a (C.sub.1
-C.sub.4) alkyl or a phenyl; an alkoxycarbonyl group of formula
COOR.sub.14 in which R.sub.14 represents tert-butyl or benzyl.
Among the compounds of formula (I), those in which R.sub.1 represents
hydrogen are preferred and among these, more particularly those in which Z
represents an indolyl group which is substituted or unsubstituted on the
nitrogen; among the groups R.sub.IV, phenyl is preferred.
The subject of the present invention is also the preparation of the
compounds of formula (I) which are prepared by a coupling reaction of an
aminothiazole of formula (II):
##STR11##
in which R.sub.1, R.sub.IV and R.sub.V have the meanings given for (I),
under the usual conditions for the acylation of an amine group, with an
acid of formula Z'COOH in which Z' represents Z or a substituted Z in
which the reactive groups of Z have been protected, and R.sub.1, R.sub.V,
R.sub.IV and Z have the same meaning as in the formula (I), or with an
activated form of the acid Z'COOH, such as an acid halide, an acid
anhydride, and preferably a mixed anhydride such as a carbonic anhydride,
or an activated ester, obtained with the reagents commonly used in peptide
synthesis.
The compounds (II) may be protected; in this case, R.degree..sub.1
represents the same substituents as R.sub.1 in which the amino group which
is present is N-protected, R.sub.IVa and R.sub.Va represent the same
substituents as R.sub.IV and R.sub.V in which the hydroxyl or amino groups
are O- and N-protected.
Once the groups have been protected, the appropriate deprotection reaction
is carried out, if necessary, after the condensation.
Numerous aminothiazoles of formula (II) are known.
The new aminothiazoles may be prepared according to one of the methods
described in particular in Bull. Soc. Chim. (C) 1963, 2498-2503.
Generally, a thiourea will be reacted with an alpha-halogenated, and
preferably alpha-brominated ketone, according to the following reaction
scheme:
##STR12##
R.sub.1, R.sub.IV and R.sub.V having the same meaning as in the formula
(II).
The preparation of various compounds (II) in which R.sub.1 represents an
aminoalkyl group is described in EP-A-0,283,390.
The alpha-halogenated ketones and the thioureas may be prepared by methods
the principles of which are described in the literature; thus, the
alpha-brominated ketones (IV) may be prepared by reacting R.sub.V CH.sub.2
COR.sub.IV with bromine in acetic acid medium or with cupric bromide in an
organic solvent such as ethyl acetate, a chlorine-containing solvent or
mixtures thereof. The starting aromatic ketones are generally prepared by
Friedel-Crafts reaction, whereas the aliphatic methyl ketones may be
prepared by reacting diazomethane with appropriate carboxylic acid
chlorides followed by hydrolysis of the corresponding diazoketone.
The alpha-chlorinated aromatic ketones may be prepared by Friedel-Crafts
reaction with the appropriate alpha-chlorinated acid chloride.
When R.sub.V represents an ester group (CH.sub.2).sub.m --COOX.sub.1, the
corresponding substituted thiazoles of formula (V) below in which
R.sub.IV, X.sub.1 and m are as defined for (I) are known or are prepared
according to known methods by reacting an alpha-bromoaceto acid or an
alpha-bromoketo ester with the thiourea according to the following
reaction scheme:
##STR13##
Depending on the value of the substituent R.sub.V, the following methods of
preparation are used:
a) --when R.sub.V represents a group --(CH.sub.2).sub.m --OH, the
corresponding substituted 2-aminothiazole of formula (VI) below, in which
m is as defined for (I), may be prepared from the above esters (V) by
reduction with an alkali metal hydride such as for example lithium
aluminium hydride in an aprotic solvent such as for example
tetrahydrofuran to give the aminoalcohol of formula:
##STR14##
the acylation of (VI) with ZCOOH leads to the compound (Ib) of formula:
##STR15##
in which formulae m, R.sub.IV and Z are as defined for (I);
b)--when R.sub.V represents an ester group --(CH.sub.2).sub.m
--O--CO--X.sub.1 or a thioester group --(CH.sub.2).sub.m --S--COX.sub.1 or
(O)q-S-X.sub.1, in which m, X.sub.1 and q are as defined for (I), the
substituted 2-aminothiazoles (VII), (VIIC) or (VIID) in which the groups
R.sub.IV, q, m, W and X.sub.1 are as defined for (I) , may be prepared
either according to the following Scheme 3:
##STR16##
or from N-protected alcohols (VI) such as defined above which are reacted
with an acid chloride such as for example acetyl chloride in a solvent
such as for example pyridine, to obtain the esters of formula:
##STR17##
in which X.sub.1, m, R.sub.IV or Z are as defined above for (I);
c)--when R.sub.V represents a carbamate --(CH.sub.2).sub.m
--O--CO--NHX.sub.1 in which m and X, are as defined for (I), the
substituted thiazoles according to the invention are prepared from the
corresponding hydroxylated compounds (Ib), by reacting an isocyanate of
formula X.sub.1 --N.dbd.C.dbd.O, in an aprotic solvent such as for example
tetrahydrofuran or dichloromethane at a temperature of between 20.degree.
C. and 100.degree. C., to give the compound (If) of formula:
##STR18##
in which X.sub.1, M, R.sub.IV and Z are as defined for
d)--when R.sub.V represents an amide --(CH.sub.2).sub.m --CONX.sub.1
X.sub.2 in which m, X.sub.1 and X.sub.2 are as defined for (I), the
thiazoles according to the invention are prepared by reacting the amine
NHX.sub.1 X.sub.2 with the corresponding ester of formula (V) or (Ia) in
the presence or in the absence of a solvent such as an alkanol, at a
temperature of between 20.degree. and 120.degree. C.; the reaction may
also be carried out in a sealed tube depending on whether the amine is
volatile, to give the compound (VIII) or (Ig) of formula:
##STR19##
in which X.sub.1, X.sub.2, M, R.sub.IV and, optionally, Z are as defined
for (I);
e)--when R.sub.V represents an amine group --(CH.sub.2).sub.m --NX.sub.1
X.sub.2, the substituted thiazoles according to the invention are
prepared, for example, by reduction of the abovedescribed amides of
formula (VIII) by reduction with an alkali metal hydride such as for
example lithium aluminium hydride in a solvent such as tetrahydrofuran, at
a temperature of between 20.degree. C. and the boiling temperature of the
solvent, to give the compound of formula:
##STR20##
the acylation of (IX) with ZCOOH gives the compound (Ih) of formula:
##STR21##
in which X.sub.1, X.sub.2, m, R.sub.IV and Z are as defined for (I)
f)--when R.sub.V represents a carbonate --(CH.sub.2).sub.m --O--COOX.sub.x,
in which m and X.sub.1 are as defined for (I), the thiazoles according to
the invention are prepared from the alcohols (Ib) by reacting them with a
chloroformate
##STR22##
in the presence of a base such as triethylamine or pyridine, to give the
compound (Ii) of formula:
##STR23##
in which X.sub.1, m, R.sub.IV and Z are as defined for (I);
g)--when R.sub.IV and R.sub.V taken together represent the group:
##STR24##
in which (X.sub.p).sub.np and u are as defined for (I) , bound via the
phenyl carbon in position 4 of the thiazole nucleus; for example, the
intermediate 4-bromo-2H-dihydro-3,4-[1]-benzoxepin-5-one of formula:
##STR25##
is prepared according to G. Fontaine et al., C. R. Acad. Sci., 1965, 258,
4583; the 2-amino-4,5-dihydro-[5,4-d]-thiazolo-[1]-benzoxepine of formula:
##STR26##
is prepared by cyclisation with the thiourea according to the usual method
described above, and then acylated to give the compound of formula:
##STR27##
in which Z is as defined for (I);
h)--when R.sub.V represents an amino group --NX.sub.2 X.sub.4, in which
X.sub.2 and X.sub.4 are as defined for (I), the substituted thiazole
according to the invention may be prepared from the
2-amino-5-bromothiazole of formula:
##STR28##
which is prepared according to J. Chem. Soc., 1947, 114, which is then:
either acylated, for example, with a substituted ZCOOH, in the presence of
BOP and a base such as triethylamine, and then this brominated derivative
obtained of formula:
##STR29##
in which R.sub.IV and Z are as defined for (I), is substituted by an amine
HNX.sub.2 X.sub.4 in an alkanol at a temperature of between 20.degree. C.
and the boiling temperature of the solvent, to give the compound of
formula:
##STR30##
in which X.sub.2, X.sub.4, R.sub.IV and Z are as defined for (I), or
substituted by the amine HNX.sub.2 X.sub.4 and then acylated in position 2
of the thiazole, the two reactions being carried out under identical
conditions to those described above;
i)--when R.sub.V represents a group --(CH.sub.2).sub.m --X, in which m=0
and X represents a (C.sub.1 -C.sub.5) alkoxy group
the corresponding 2-aminothiazole is prepared from 2-bromo-2-
alkoxy-1-phenylethanone, which is optionally substituted on the phenyl, to
give the product of formula:
##STR31##
in which R.sub.IV is as defined above and X represents a (C.sub.1
-C.sub.5) alkoxy, which is then acylated as indicated above to give the
compounds (Im) of formula:
##STR32##
in which R.sub.IV and Z are as defined for (I) and X is as defined above
for (XI'), or one of their salts.
The compounds of formula (XI') are new intermediates which are also within
the invention.
Some of the acids ZCOOH or Z'COOH, are known and are even available
commercially; the others are prepared using the methods known for similar
molecules.
Thus, the indolecarboxylic acids, hereafter called Z"COOH; of formula:
##STR33##
in which R.sub.9 represents an alkoxycarbonylalkylene group may be
prepared from indolecarboxylic acids, which are commercially available or
which are obtained by conventional methods, using the reaction scheme 4
below.
##STR34##
in which Hal represents a halogen atom and Q represents a benzyl group.
The benzyl esters of scheme (4) are prepared by reacting the corresponding
acid with benzyl alcohol, in the presence of one of the acid
group-activating agents which are commonly used in peptide synthesis, such
as:
1,1'-carbonyldiimidazole for which reference can be made to Synthesis 1982,
p. 833,
N,N-dicyclohexylcarbodiimide, in the presence of 4-dimethylaminopyridine,
for which reference can be made to J. Org. Chem. 1990, 55 (4), p. 1390,
benzotriazolyloxytris(dimethylamino)phosphonium hexafluorophosphate for
which reference can be made to Synthesis, 1977, p. 413.
The base used during the binding of R.sub.9 to the nitrogen of the benzyl
ester is preferably an anhydrous strong base such as an alkali metal
hydride; the reaction mixture is in this case an aprotic polar solvent,
which is stable in the presence of a strong base such as dimethylformamide
or dimethoxyethane; the reaction is carried out at a temperature of
between about 15.degree. C. and 80.degree. C.
The removal of the benzyl group after the N-alkylation, is carried out in a
conventional manner by reacting not less than one equivalent of hydrogen,
in the presence of a catalyst such as palladium on carbon, with the ester
dissolved in an alcohol or dimethylformamide, optionally under a mild
pressure.
Moreover, some ZCOOH acids are not very stable or carry a group which may
react during the coupling with aminothiazole and it is preferable to use
them in a protected form Z'COOH.
Thus, the derivatives (I) in which Z represents:
##STR35##
and in which (X.sub.i).sub.ni represents the optional substituents, may be
prepared from the compounds obtained by coupling the aminothiazole to
compounds of the indolecarboxylic acid Z'COOH, of formula:
##STR36##
in which Q' represents a group which is normally used for the protection
of NH.sub.2 groups in amino acid coupling reactions, such as
##STR37##
the protective group Q may be removed from the compound of formula:
##STR38##
which is obtained after coupling to the derivative (II), by conventional
deprotection methods.
BOC may be removed by pyrolysis, in the absence of solvent, at a
temperature of between 180.degree. and 200.degree. C.
The indolecarboxylic acids Z"COOH in which R.sub.9 is COOC(CH.sub.3).sub.3
or COOCH.sub.2 C.sub.6 H.sub.5, may be prepared by reacting tert-butyl
dicarbonate or benzyl chloroformate with Z"COOH in which R.sub.9 =H, in
the presence of a base such as triethylamine or 4-dimethylaminopyridine,
in a solvent such as acetonitrile or methylene chloride.
The acids Z"COOH in which R.sub.9 is an acyl group, may be prepared by
reacting the acid chloride or anhydride with Z"COOH, in which R.sub.9 =H,
in the presence of one equivalent of triethylamine and
4-dimethylaminopyridine, for example in dichloromethane.
The acid chloride of formula ZCOCl, may be prepared, in particular by
reacting SOCl.sub.2 or a mixture of POCl.sub.3 and P.sub.2 O.sub.5 with
the corresponding acid, in general in the absence of solvent and at the
reflux temperature of the reaction mixture.
Among the activated esters of formula ZCOOY", Z'COOY" or Z"COOY", those in
which
Y" represents
##STR39##
may be prepared by reacting 1-hydroxybenzothiazole with the acid in the
presence of dicyclohexylcarbodiimide according to the procedure described
in J. Am. Chem. Soc. 1971, 93, 6318-6319 (1971), or by reacting
1-benzothiazolyloxytris(dimethylamino)phosphonium hexafluorophosphate
according to the procedure described in Synthesis, 1976, 751-752.
The coupling of the aminothiazole (II) with the acid in activated ester
form, may be carried out in a solvent the nature of which is chosen
according to the solubility of the compounds and the type of activation of
the acid group, preferably in the presence of a base, for example a
tertiary amine such as triethylamine; the reaction is generally carried
out at a temperature of between 0.degree. C. and 30.degree. C.
When the compounds of formula (I) contain a carboxylic acid group in Z,
they are prepared by hydrolysis of an ester preferably in a base medium,
for example by reaction of an inorganic base such as an alkali metal
hydroxyl, in a dilute alcoholic medium or by acid hydrolysis in the case
of a tert-butyl ester.
The addition salts of the compounds of formula (I) with acids or bases are
prepared in the usual manner by introducing the acid or the base into a
solution of the compound of formula (I). The salt is isolated, depending
on its solubility properties, after evaporation of the solvent or addition
of a non-solvent.
The compounds of formula (I) and their salts inhibit the binding of
cholecystokinin to its receptors. They are more or less selective for the
A or B type receptors, and for more or less potent gastrin antagonists.
Their affinity for the CCK A receptor has been determined in vitro using
the method described below, the principle of which is that mentioned in
Life Sciences, 1985, 37, (26), 2483-2490; it consists in determining the
displacement of iodinated CCK 8S from its receptors, in a rat pancreas
homogenate: aliquot amounts of pancreatic membrane suspension (100
1/2.mu.g of proteins per ml) in a TRIS-HCl buffer (50mM), of pH=7.4,
containing MgCl.sub.2 (5 mM), bacitracin (0.1 mg/ml),
methylphenylmethanesulphonic acid fluoride (0.1 mg/ml), are incubated for
40 minutes at 25.degree. C. in the presence of iodinated CCK 8S (2000
Ci/mmol, equivalent to 50 mM final concentration) and of increasing
concentrations of the test substance; the reaction is stopped by
centrifugation after 40 minutes. After removal of the supernatant, the
radioactivity of the pellet is measured. Moreover, nonspecific binding is
determined in the presence of CCK 8S at a concentration of 1.mu.M.
Under these conditions, the concentration inhibiting binding by 50%
(IC.sub.50) is less than 10.sup.-7 M for the products of the invention,
and, for many, is about 10.sup.-10 M.
Their affinity for the CCK B receptors was determined by studying the
displacement of iodinated CCK 8S from its specific receptors which are
present in guinea pig cortex homogenates, using the same procedure as for
the CCK A receptors, but for a membrane suspension containing 600 .mu.g of
proteins/ml with a HEPES buffer (10 mM) at pH 6.5, containing NaCl (130
mM), MgCl.sub.2 (5 mM), EDTA (1 mM) and bacitracin (250 mg/ml) and the
incubation being for 2 hours.
At a concentration of 10.sup.-5 M, all the products displace more than 25%
of the labelled CCK 8S from the B receptor; some have a IC.sub.50 of about
10.sup.-9 M.
The affinity for the gastrin receptor of the most CCK B receptor-specific
compounds was studied according to the method described below, the
principle of which is that mentioned in J. Receptor. Res., 1983, 3 (5)
647-655; aliquots of guinea pig gastric glands in a HEPES buffer, pH=7.4
(24.5 mill), containing NaCl (98 mM), KC.sub.1 (6 mM), NaH.sub.2 PO.sub.4
(2.5 mM), pyruvate (5 mM), CaCl.sub.2 (0.5 mM), MgCl.sub.2 (1 mM), glucose
(11.5 mM), glutamine (1 mM), bovine albumin (0.4 g/100 ml) were incubated
for 90 minutes at 37.degree. C. in a water bath in the presence of
iodinated gastrin (2-17) (2000 Ci/mmol; 70 pill) and of increasing
concentrations of the test products. The reaction was stopped by
centrifugation and the radioactivity of the pellet measured; the
non-specific binding was determined in the presence of gastrin (2-17) at 1
.mu.M. The compounds of the invention have a IC.sub.50 of between
10.sup.-5 M and 10.sup.-9 M.
It has also been shown that the compounds of the invention have an
inhibitory activity with respect to that of CCK. This has been
demonstrated in vitro by measuring the inhibition by the test products, of
CCK 8S,-stimulated secretion of amylase by rat acinar cells, according to
a method similar to that described in J. Biol. Chem., 1979, 254 (12),
5321-5327, but with guinea pig pancreatic tissues. The compounds have a
IC.sub.50 of 10.sup.-6 M to 10.sup.-9 M.
Finally, in vivo, in mice, the compounds having a good affinity for the CCK
A receptors antagonised the inhibition of the emptying of the stomach
induced by subcutaneous administration of CCK 8S in the procedure
described in Life Sciences, 1986, 39, 1631-1638; the ED.sub.50 (effective
dose 50) thus determined is substantially lower than that of proglumide, a
known gastrin antagonist.
As these compounds are not very toxic, they can be used as medicines for
the treatment of physiological disorders resulting from a hypersecretion
of these peptides or from a dysregulation of the biological hormonal
systems in which they are involved, in the region of the intestinal sphere
or in the central nervous system, depending on their specificity.
Reference can be made to the review of the therapeutic applications of the
antagonists of CCK and gastrin, published in "Proceedings of International
Symposium on Gastrin and Cholecystokinin" 7-11 Sept. 1987 --Ed. J. P.
Bali, J. Martinez --Elsevier Science Pub. BV.
In particular, the antagonists of CCK will be useful in the treatment of
intestinal dyskinesias such as irritable colon syndrome, in the treatment
of acute or chronic pancreatitis or in that of pancreatic carcinomas, but
also for regulating appetite, or, combined with opium-containing
analgesics, in the treatment of pain.
As for the more selective gastrin antagonists, they will be useful in the
treatment and prevention of gastric ulcers, in the treatment of
Zollinger-Ellison syndrome, in that of hyperplasia of the G cells of the
antrum or for patients with cancerous tumours of the oesophagus, of the
stomach or of the intestine.
Among the antagonists of cholecystokinin at the level of the A receptors,
the following compounds are preferred:
2-[(1-Carboxymethyl-2-indolyl)carbonylaminol-4-phenyl-5-acetoxyethylthiazol
e.
2-[(2-Indolyl)carbonylamino]-4-phenyl-5-acetoxyethylthiazole.
The medicines according to the invention contain at least one of the
compounds of the formula (I) or one of its salts with a pharmaceutically
acceptable acid or base, optionally combined with the usual excipients so
as to constitute a pharmaceutical composition which can be administered in
a conventional manner via the oral, transmucous, parenteral or rectal
route. The doses administered depend on the nature and the severity of the
disease, on the compound and on the route of administration. They will be
generally between 20 and 100 mg per day in an adult man via the oral route
and 3 to 10 mg by injection.
The pharmaceutical compositions according to the invention can be, for oral
administration, provided in the form of tablets, pills, hard gelatin
capsules or granules or alternatively in the form of a solution,
suspension or gel. For parenteral administration, the compositions of the
invention will be provided in the form of a solution, suspension or
emulsion in an oil or any solvent for injection, optionally aqueous based
containing conventional adjuvants for this type of formulation.
For local administration, on the skin or on the mucous membranes, the
compositions according to the invention will be provided as a cream,
ointment or in the form of a transdermal device, whereas for rectal
administration, they will be in the form of suppositories and rectal
capsules.
In the following text, examples of implementation of the invention are
described as well as methods of preparing certain synthesis intermediates
of formula II and IV. The melting points, m.p., indicated were determined
in capillary tubes. The nuclear magnetic resonance (NMR) spectra were
recorded relative to tetramethylsilane.
PREPARATION A
2-Aminothiazole substituted in position 5 by a group (CH.sub.2).sub.m
X.sub.1
2-Amino-4-(2,4-dimethoxyphenyl)-5-benzylthiazole.
##STR40##
A) 1-(2,4-Dimethoxyphenyl)-3-phenylpropan-1-one is prepared according to E.
Thomas et al., J. Med. Chem., 1985, 28, 442-446 via the Friedel-Crafts
reaction.
B) 1-(2,4-Dimethoxyphenyl)-2-bromo-3-phenylpropan-1-one is prepared
according to conventional methods by bromination using bromine in a
solvent such as dichloromethane or carbontetrachloride.
C) 2-Amino-4-(2,4-dimethoxyphenyl)-5-benzylthiazole.
4.35 g of thiourea are added to 10 g of the brominated derivative prepared
above, dissolved in 100 ml of 95.degree. ethanol and the reaction mixture
is refluxed for three hours. The mixture is concentrated under vacuum and
the residue is taken up in dichloromethane and then washed with a
saturated solution of Na.sub.2 CO.sub.3. The organic phase is separated by
decantation, dried over MgSO.sub.4 and concentrated under vacuum. The
residue crystallises from 50 ml of dichloromethane.
m=7.10 g
m.p.=202.degree.-203.degree. C.
By carrying out the procedure as indicated above, the 2-aminothiazoles
described in Table 1 below are prepared.
TABLE 1
______________________________________
##STR41##
X(CH.sub.2).sub.m
r.sub.4 r'.sub.4 m.p; .degree.C.
______________________________________
##STR42## OCH.sub.3 OCH.sub.3
119
##STR43## OCH.sub.3 OCH.sub.3
163-164
##STR44## OCH.sub.3 OCH.sub.3
162
##STR45## OCH.sub.3 OCH.sub.3
121
##STR46## OCH.sub.3 OCH.sub.3
176
Br H H 107
______________________________________
PREPARATION B
2-Aminothiazole substituted in position 5 by a group --(CH.sub.2).sub.m
--CO.sub.2 X.sub.1 or --(CH.sub.2).sub.m --CH.sub.2 OH
A) 2-Amino-4-phenyl-5-methoxycarbonylmethylthiazole.
(II): R.sub.1 =H; R.sub.IV =--C.sub.6 H5; R.sub.V =--CH.sub.2 --CO.sub.2
CH.sub.3
Prepared according to E. Knott, J. Chem. Soc., 1945, 455.
B) 2-Amino-4-phenyl-5-hydroxyethylthiazole.
5 g of the amino ester prepared above is added to a suspension of 2 g of
lithium aluminium hydride in 100 ml of tetrahydrofuran cooled to 0.degree.
C., and the reaction mixture is refluxed for two hours. 2 ml of water, 1
ml of concentrated NaOH and 6 ml of water are then added successively
after cooling on an ice bath and then the reaction mixture is stirred
overnight. The inorganic matter is separated by filtration and the mother
liquors are concentrated under vacuum. The residue is taken up in
dichloromethane, washed with water and the organic phase is successively
decanted, dried over MgSO.sub.4 and concentrated under vacuum. The residue
is chromatographed on a silica gel, eluent dichloromethane/methanol 100+3
(v/v).
Concentration of the pure fractions gives 4 g of the expected alcohol.
m.p.=121.degree. C.
By carrying out the procedure as indicated above, the 2-aminothiazoles
described in Table 2 below are prepared.
TABLE 2
______________________________________
##STR47##
T r.sub.4 r'.sub.4 m m.p; .degree.C.
______________________________________
CO.sub.2 CH.sub.3
H H 1 231
OH H H 2 121
COOCH.sub.2 CH.sub.3
H H 0 175
COOCH.sub.2 CH.sub.3
H H 1 162
COOCH.sub.2 CH.sub.3
2-OCH.sub.3
4-OCH.sub.3
1 117-118
______________________________________
PREPARATION C
2-Aminothiazoles substituted in position 5 by a group
##STR48##
2-Amino-5-(l-adamantyl-1-carbonyloxyethyl)-4-phenylthiazole
##STR49##
A. 4-(1-Adamantylcarbonyloxy)-1-phenyl-1-butane.
The caesium salt of 1-adamantylcarboxylic acid is prepared according to J.
Org. Chem., 1977, 42, 8, 1286, from 12 g of 1-adamantylcarboxylic acid and
10.96 g of caesium carbonate. The salt obtained is dissolved in 70 ml of
DMF and then 18 g of 4-iodo-1-phenylbutan-1-one are added and the reaction
mixture is refluxed overnight. The DMF is evaporated under vacuum, and the
residue resuspended in a 5% solution of Na.sub.2 CO.sub.3 and extracted
with CH.sub.2 Cl.sub.2. The organic phase is washed with water and then
dried over Na.sub.2 SO.sub.4. It is concentrated under vacuum and the
residue is chromatographed on a silica gel, eluent CH.sub.2 Cl.sub.2.
Concentration of the pure fractions gives 10 g of the expected compound.
B. 2-Amino-5-(1-adamantyl-1-carbonyloxyethyl)-4-phenylthiazole.
10 g of the compound prepared above are dissolved in 100 ml of CCl.sub.4.
4.9 g of bromine dissolved in 50 ml of CCl.sub.4 are added and the
reaction mixture is left stirring for 30 minutes. It is washed with water,
and the organic phase decanted, dried over MgSO.sub.4, filtered and
concentrated under vacuum. The residue is taken up in 50 ml of 95.degree.
ethanol. 3.9 g of thiourea are added to the solution and the reaction
mixture is left overnight at room temperature. The mixture is concentrated
under vacuum, and the residue is taken up in CH.sub.2 Cl.sub.2, washed
with a 5% solution of NaHCO.sub.3, and the organic phase is decanted,
dried over MgSO41 filtered and concentrated under vacuum. The residue is
taken up in ether and dried.
m=6.8 g
m.p.=167.degree. C.
By carrying out the procedure as indicated above, the 2-aminothiazoles
described in Table 3 below are prepared.
TABLE 3
______________________________________
##STR50##
X.sub.1 m.p; .degree.C.
______________________________________
##STR51## 109-110
##STR52## 129-130
##STR53## 147-149
##STR54## 190-192
##STR55## 107-108
______________________________________
PREPARATION D
2-Aminothiazoles substituted in position 5 by a group --(CH.sub.2).sub.m X
in which X represents a group --NX.sub.1 X.sub.2 with X.sub.1 =X.sub.2 =H
Preparation of 2-amino-5-aminoethyl-4-phenylthiazole.
(II) : .sub.1,=H; R.sub.IV =--C.sub.6 H.sub.5 ; R.sub.V =--CH.sub.2
CH.sub.2 NH.sub.2
A) 4-Phthalimido-1-phenylbutan-1-one.
27.4 g of 4-iodo-1-phenylbutan-1-one and 27 g of potassium phthalimide are
heated in 100 ml of DMF at 120.degree. C. for 24 hours. The DMF is
concentrated under vacuum and the residue is successively washed with
water and with a 1N solution of NAOH and extracted with ethyl acetate. The
organic phases are decanted, dried over MgSO.sub.4, filtered and
concentrated under vacuum.
m=11 g.
B) 2-Amino-5-phthalimidoethyl-4-phenylthiazole.
9.6 g of the compound prepared above are dissolved in 50 ml of CC.sub.1,
and 80 ml of CH.sub.2 Cl.sub.2. A solution of 5.6 g of bromine in 30 ml of
CCl.sub.4 is added dropwise to the solution. The reaction mixture is
washed with water, and the organic phases are dried over MgSO.sub.4,
filtered and concentrated under vacuum. The residue is taken up in 70 ml
of ethanol, and 4.5 g of thiourea are added and the reaction mixture is
left overnight at room temperature.
The mixture is cooled, and the hydrobromide is separated by filtration,
washed with ethanol and then stirred vigorously in a 5% Na.sub.2 CO.sub.3
/ethyl ether mixture. The crystals are filtered.
m=8 g. F=208.degree. C.
C) 2-Amino-5-aminoethyl-4-phenylthiazole.
8 g of the product prepared above are treated with 1.5 g of hydrazine
hydrate dissolved in 100 ml of absolute ethanol. The reaction mixture is
refluxed overnight and then the following operations are carried out
successively: the ethanol is concentrated under vacuum, the residue is
taken up in water, acidified by the addition of concentrated HCl up to
pH=1, the phtalazinedione separated by filtration, the aqueous phase,
cooled on an ice bath, is alkalinised by the addition of concentrated NAOH
up to pH=9, the precipitate is filtered, washed with water and dried in an
oven.
m=3.7 g
m.p=136.degree.-137.degree. C.
PREPARATION E
2-Aminothiazoles substituted in position 5 by a group --(CH.sub.2).sub.m X
in which X represents a group --NX.sub.1 X.sub.2 in which X.sub.1 =H and
X.sub.2 =--CO--CH.sub.3
2-Amino-5-(2-acetylamino-1-ethyl)-4-phenylthiazole.
(II): R.sub.1 =H; R.sub.IV =--C.sub.6 H.sub.5 ; R.sub.V =CH.sub.3
CONH(CH.sub.2).sub.2 --
1 g of the 2-aminothiazole obtained according to Preparation D, dissolved
in 60 ml of THF, in the presence of 0.7 ml of triethylamine, is treated
with 0.44 ml of acetic anhydride dissolved in 20 ml of THF. The reaction
mixture is left at room temperature for 2 hours and concentrated under
vacuum. The residue is washed with a solution of NaHCO.sub.3, and the
precipitate is separated by filtration, washed with water and dried.
m=1.12 g
m.p.=208.degree.-209.degree. C.
Using the 2-aminothiazole obtained according to Preparation D, and by
carrying out the procedure according to Preparation E, the intermediate
compounds described in Table 4 below are prepared.
TABLE 4
______________________________________
##STR56##
T m.p; .degree.C.
______________________________________
##STR57## 157-158
##STR58## oil
##STR59## 171
##STR60## 151
______________________________________
PREPARATION F
2-Amino-4,5-dihydro-[5,4-d]-thiazolo-[l]-benzoxepin
##STR61##
A) 4-Bromo-4-2H-3,4-dihydro-[1]-benzoxepin-5-one is prepared according to
G. Fontaine, P. Maitte, C. R. Acad. Sci., 1964, 258, 4583.
B) 2-Amino-4,5-dihydro-[5,4-d]-thiazolo-[1]-benzoxepin.
2.05 g of thiourea are added to 0.027 mole of brominated derivative
solubilised in 100 ml of ethanol. The mixture is refluxed for 3 hours. The
ethanol is evaporated, the residue is taken up in an aqueous solution of
sodium carbonate. It is extracted with ethyl acetate, and the organic
phase is dried over Na.sub.2 SO.sub.4 and evaporated to dryness. 2.4 g of
white crystals are obtained.
m.p.=216.degree. C.
PREPARATION G
2-Aminothiazoles substituted in position 5 by a group --(CH.sub.2).sub.m
--X in which m =0 and X represents a (C.sub.1 -C.sub.5) alkoxy group or a
halogen
##STR62##
(II): R.sub.1 =H; R.sub.IV =--C.sub.6 H.sub.5 ; R.sub.V =--OCH.sub.3
15.65 g of 2-bromo-2-methoxy-1-phenylethanone and 5.52 g of thiourea are
dissolved in 70 ml of methanol. The reaction mixture is refluxed overnight
and then concentrated under vacuum. The residue is taken up in a 10%
solution of Na.sub.2 CO.sub.3 in water, the mixture is extracted with
CH.sub.2 Cl.sub.2, the organic phase is separated and successively dried
over Na.sub.2 SO.sub.4, filtered and concentrated under vacuum. The
residue is recrystallised from isopropyl
m=7.5 g
m.p.=96.degree. C.
TABLE 5
______________________________________
##STR63##
r.sub.4
m.p; .degree.C.
______________________________________
2-Cl 72
2-OCH.sub.3
159-160
4-CH.sub.3
112-114
______________________________________
PREPARATION H
Preparation of the indolecarboxylic acids
A) 1-tert-butyloxycarbonylmethylindole-2-carboxylic acid
a) Benzyl indole-2-carboxylate.
5 g of N,N'-carbonyldiimidazole are introduced into a solution of 5 g of
indole-2-carboxylic acid in 50 ml of dry tetrahydrofuran; after stirring
for 12 hours at room temperature, 3.7 g of benzyl alcohol are added and
the reaction mixture is heated at its reflux temperature; the latter is
maintained for 8 hours before removing the solvent by distillation under
reduced pressure. The residue is dissolved in ethyl acetate and the
organic phase is washed with a 1N aqueous solution of NAOH and then dried
before evaporation of the solvent.
The yellow residue is recrystallised from isopropanol.
m.p.=136.degree. C.
yield=85%.
b) Benzyl 1-tert-butoxycarbonylmethylindole-2-carboxylate.
80% sodium hydride in oil is added in portions (0.075 mole; 2.25 g) to a
solution of benzyl indole-2-carboxylate (0.072 mole; 18.18 g) in 200 ml of
dimethylformamide, under a nitrogen atmosphere, at a temperature of
between 0.degree. C. and 5.degree. C. The mixture is allowed to
reequilibrate to room temperature and the mixture is stirred for 1 hour.
tert-Butyl bromoacetate (0.072 mole; 14 g) is then added dropwise at
10.degree. C. The reaction mixture is left for 3 hours at room
temperature. The dimethylformamide is evaporated and the residue is
successively taken up in water, extracted with methylene chloride, and the
organic phase dried over sodium sulphate and evaporated to dryness. 23.8 g
of white crystals are obtained by crystallisation of the residue from
diisopropyl ether.
m.p.=95.degree. C.
C) 1-tert-Butoxycarbonylmethylindole-2-carboxylic acid.
The ester prepared above (0.065 mole; 23.8 g) is solubilised in a mixture
of 400 ml of ethanol and 100 ml of dimethylformamide. 1 g of 5% palladium
on carbon is added and the mixture is hydrogenated under atmospheric
pressure at room temperature. After stirring for 30 minutes, the
theoretical volume of hydrogen is absorbed. The catalyst is filtered on
talc and the solvents are evaporated to dryness. A crystallised residue is
obtained, which is washed with diisopropyl ether. 15.3 g of white crystals
are obtained.
m.p.=177.degree. C.
B) 1-Acetylindole-2-carboxylic acid.
A mixture of indole-2-carboxylic acid (0.06 mole; 10 g), triethylamine
(0.15 mole; 21.25 g), acetic anhydride (0.075 mole; 7.5 g) and
4-dimethylaminopyridine (0.006 mole; 0.8 g), in methylene chloride is
stirred at room temperature for 18 hours. The reaction mixture is then
poured into an aqueous solution of buffer pH=2. The precipitate formed is
filtered and then dried in an oven under vacuum. The methylene chloride
phase is decanted, dried over sodium sulphate and evaporated to 3/4. A
second crop of 1-acetylindole-2-carboxylic acid precipitates. The two
crops are combined to give 9.4 g of beige crystals.
m.p.=168.degree. C.
C) 1-Benzyloxycarbonylaminoindole-2-carboxylic acid.
8 g of indole-2-carboxylic acid are dissolved in 120 ml of dichloromethane
and then 10 g of triethylamine and 1 g of 4-dimethylaminopyridine are
added.
The reaction mixture is stirred and then cooled to 0.degree.-5.degree. C.
8.5 g of benzyloxycarbonyl chloride are added dropwise at a temperature of
less than 5.degree. C. The mixture is left stirring overnight and then
concentrated under vacuum. The residue is taken up in 500 ml of ethyl
acetate and then filtered. The mother liquors are concentrated under
vacuum and taken up in 50 ml of dichloromethane. The mother liquors are
filtered and concentrated under vacuum.
m=2.4 g of oil
NMR (DMSO): 2 H at 5.38 (s, CH.sub.2 --C.sub.6 H.sub.5); 10 H between 7.0
and 8.0 (m; Jar).
D) 1-tert Butyloxycarbonylindole-2-carboxylic acid
30 ml of a solution of 6 g of di-tert-butyl dicarbonate are introduced
dropwise into 30 ml of a solution of 4 g of indole-2-carboxylic acid, 4 ml
of triethylamine and 0.4 g of 4-dimethylaminopyridine in acetonitrile.
After stirring for 2 hours at room temperature and removing the
precipitate formed, the acetonitrile is removed by distillation and the
reside is dissolved in methylene chloride. The organic phase is washed
with water, dried and concentrated to dryness.
m.p.=117.degree. C.; yield 66%
yield=66%.
EXAMPLE 1
2-[(2-Indolyl)carbonylamino]-4-(2,4-dimethoxyphenyl)-5-benzylthiazole
##STR64##
1.96 g of 2-amino-4-(2,4-dimethoxyphenyl)-5-benzylthiazole prepared above
according to Preparation A, 1.22 g of 1-acetylindole-2-carboxylic acid,
0.85 g of triethylamine and 2.95 g of BOP are dissolved in 20 ml of
dimethylformamide.
The reaction mixture is stirred for 24 hours at room temperature and then
poured into a buffer solution, pH=2. A yellow precipitate is separated by
filtration, washed with water and dissolved in ethyl acetate. The solution
is washed successively with a buffer solution, pH=2, with water, with a 5%
solution of NaHCO.sub.3 and with water, and then dried over MgSO.sub.4 and
concentrated under vacuum. The residue is purified by chromatography on a
silica gel, eluent:dichloromethane/ethyl acetate 98/2 (v/v).
Concentration of the pure product fractions gives a residue which is
treated, with stirring for 24 hours, with 3 g of Na.sub.2 CO.sub.3 in 80
ml of methanol. The methanol is concentrated under vacuum and the residue
is taken up in a water/ether mixture. A white precipitate is separated by
filtration and washed with ether.
m=0.97 g
m.p.=201.degree.-202.degree. C.
The compounds according to the invention, which are described in Table 6
below, are prepared in the same manner.
TABLE 6
______________________________________
##STR65##
Example n.degree.
R.sub.V m.p; .degree.C.
______________________________________
##STR66## 225
3
##STR67## 272
4
##STR68## 262
5
##STR69## 225
6
##STR70## 283
______________________________________
EXAMPLE 7
2-[(1-tert-Butoxycarbonyloxymethyl-2-indolyl)carbonylamino]-4-phenyl-5-hydr
oxyethylthiazole.
##STR71##
2 g of the aminoalcohol prepared above (according to Preparation B, Table
2), 2.75 g of 1-tert-butoxycarbonylindole-2-carboxylic acid, 1.4 g of
triethylamine and 4.9 g of BOP are dissolved in 15 ml of
dimethylformamide. After leaving overnight at room temperature, the
reaction mixture is poured into phosphate buffer, pH=2. A precipitate is
separated by filtration, washed with water and dissolved in ethyl acetate.
The solution is successively washed with a 5% solution of NaHCO.sub.3 and
with water, separated by decantation, and the organic phase is dried over
MgSO.sub.4 and concentrated under vacuum.
The residue is purified by chromatography on a silica gel, eluent
dichloromethane/methanol 100+0.5 (v/v).
The first product eluted corresponds to the deacylated compound (O and N
acylation, m.p.=70.degree. C.).
The expected product is the second to be eluted.
m=1.2 g
m.p.=180.degree.-181.degree. C.
EXAMPLE 8
2-[(1-tert-Butoxycarbonylmethyl-2-indolyl)carbonylamino]-4-phenyl-5-acetoxy
ethylthiazole
##STR72##
0.30 g of the product prepared above is suspended in 5 ml of pyridine.
1.2 ml of acetic anhydride are added and the reaction mixture is stirred
overnight at room temperature. The mixture is then poured into sulphate
buffer, pH=2, and a precipitate is separated by filtration, washed with
water and then taken up in dichloromethane. The solution is successively
washed with a 5% solution of NaHCO.sub.3, separated by decantation, and
the organic phase is dried over MgSO.sub.4, filtered and concentrated
under vacuum. The residue is purified by chromatography on a silica gel,
eluent : dichloromethane/ethyl acetate 98/2 (v/v).
m=0.16 g
NMR (DMSO): 9 H at 1. 4 8 (S, t-BuO.sub.2 C); 3 H at 2.00 (S, CH.sub.3
CO.sub.2) 2 H at 3.24 (T, J=7 Hz, CH.sub.2 thiazole); 2 H at 4.30 (T, J=7
Hz, CH.sub.2 OAc); 2 H at 5.40 (S, CH.sub.2 CO.sub.2 t-Bu); 10 H between
7.2 and 7.9 (M, Har); 1 H at 12.8 (S, NHCO).
EXAMPLE 9
2-[(1-Carboxylmethyl-2-indolyl)carbonylamino]-4-phenyl-5-acetoxyethylthiazo
le
##STR73##
0.15 g of the compound prepared above is solubilised in 2 ml of anisole and
10 ml of trifluoroacetic acid.
The mixture is left for 45 minutes at room temperature and then
concentrated under vacuum. The residue obtained is washed with a mixture
of hexane and diethyl ether (50/50) and then dried.
m=0.14 g
m.p.=217.degree.-218.degree. C.
EXAMPLE 10
2-[(1-Acetyl-2-indolyl)carbonylamino]-4-(2,4-dimethoxyphenyl)-5-ethoxycarbo
nylmethylthiazole
##STR74##
1.5 g of 2-amino-4-(2,4-dimethoxyphenyl)-5-ethoxycarbonylmethylthiazole, 1
g of 1-acetylindole-2-carboxylic acid, 0.7 ml of triethylamine and 2.39 g
of BOP are dissolved in 15 ml of dichloromethane. The reaction mixture is
stirred overnight at room temperature and then concentrated under vacuum.
The residue is taken up in ethyl acetate and the solution is successively
washed with a buffer solution, pH=2, with a 5% solution of NaHCO.sub.3 and
with water, and then the organic phase is dried over MgSO.sub.4 and
concentrated under vacuum. The residue is purified by chromatography on a
silica gel, eluent:dichloromethane/ethyl acetate 100/2.5 (v/v).
m=1.2 g
m.p.=130.degree.-135.degree. C.
EXAMPLE 11
2-[(2-Indolyl)carbonylamino]-5-ethoxycarbonyl-4-phenylthiazole,
##STR75##
By carrying out the procedure according to Example 10 which is described
above, the compound
2-[(1-acetyl-2-indolyl)carbonylamino]-4-phenyl-5-ethoxycarbonylthiazole
(1.5 g) is prepared and dissolved in 100 ml of ethanol in the presence of
0.6 g of Na.sub.2 CO.sub.3. The mixture is stirred at room temperature for
48 hours and then concentrated under vacuum. The residue is triturated in
water and then in a minimum amount of dichloromethane, filtered and dried.
m=1.1 g
m.p.=248.degree. C.
EXAMPLE 12
2-[(2-Indolyl)carbonylamino]-4-(2,4-dimethoxyphenyl)-5-carboxymethylthiazol
##STR76##
0.5 g of
2-[(1-acetyl-2-indolyl)carbonylamino]-4-(2,4-dimethoxyphenyl)-5-ethoxycarb
onylmethylthiazole, prepared above according to Example 10, is dissolved in
10 ml of 950 ethanol and then 1.5 ml of 2N NAOH are added. The reaction
mixture is stirred overnight at room temperature and then concentrated
under vacuum. The residue is taken up in a buffer solution, pH=2, a
precipitate is separated by filtration, washed with water, filtered and
then rinsed with ether.
m=0.28 g
m.p.=284.degree. C.
By carrying out the procedure according to Examples 7 to 12 above, the
compounds described in Table 7 below are prepared.
TABLE 7
______________________________________
##STR77##
Example No.
T m R.sub.9 m.p.; .degree.C.
______________________________________
13 CO.sub.2 CH.sub.3
1 H 254
14 CO.sub.2 CH.sub.3
2 H 181
15 OH 2 CH.sub.2 CO.sub.2 H
131
16 OH 2 H 242
17 OH 3 H 213
18 OCOCH.sub.3 2 H 168
19 OCOCH.sub.3 3 H 192
20 OCOC.sub.6 H.sub.5
2 CH.sub.2 CO.sub.2 H
216
21 OCO-tert-Bu 2 H 229
22 CO.sub.2 H 1 H 266
23 CO.sub.2 H 2 H >300
24 CO.sub.2 H 2 CH.sub.2 CO.sub.2 H
239-240
25 CO.sub.2 H 1 CH.sub.2 CO.sub.2 H
199-200
26 CO.sub.2 CH.sub.3
2 CH.sub.2 CO.sub.2 H
202-203
27 CO.sub.2 CH.sub.3
1 CH.sub.2 CO.sub.2 H
183-185
28
##STR78## 1 CH.sub.2 CO.sub.2 H
252
29
##STR79## 1 CH.sub.2 CO.sub.2 H
233-234
30
##STR80## 1 CH.sub.2 CO.sub.2 H
241-242
______________________________________
EXAMPLE 31
2-[(2-Indolyl)carbonylamino]-4-phenyl-5-[2-(1-pyrrolidinocarbonyl)-1-ethyl]
thiazole
##STR81##
0.5 g of the ester described in Example 14 is added to 5 ml of pyrrolidine,
the mixture is stirred overnight at room temperature and then poured into
a buffer solution, pH=2. A precipitate is separated by filtration and then
dissolved in ethyl acetate. The solution is washed with a buffer solution,
pH=2, and then with water, and the organic phase is separated by
decantation, dried over MGSO.sub.4 and concentrated under vacuum.
m=0.48 g
m.p.=179.degree. C.
By carrying out the procedure according to Example 10 above, compounds 32
to 51, which are described in Table 8 below, are prepared.
TABLE 8
______________________________________
##STR82##
Example No.
T m r.sub.4
m.p.; .degree.C.
______________________________________
32 COOCH.sub.3 1 4-F 224-225
33 COOC.sub.2 H.sub.5
1 2-Cl 178
34
##STR83## 1 H 180
35
##STR84## 1 H 239
36
##STR85## 1 4-F 243-244
37
##STR86## 1 2-Cl 187-188
38 NH.sub.2 2 H 202-203
39
##STR87## 2 H 261-262
40
##STR88## 2 4-F 188-189
41
##STR89## 2 H 208-209
42
##STR90## 2 H 223-224
43
##STR91## 2 H 264
44
##STR92## 2 H 248-249
45
##STR93## 2 H 275-276
46
##STR94## 2 H 209-210
47
##STR95## 2 H 196-197
48
##STR96## 2 H 218-219
49
##STR97## 2 H 140- 142
50
##STR98## 2 H 270-271
51
##STR99## 2 H 212-213
______________________________________
EXAMPLE 52
2-[(2-Indolyl)carbonylamino]-4-phenyl-5-phenylaminocarbonyloxyethylthiazole
##STR100##
A)
2-[(1-Acetyl-2-indolyl)]carbonylamino-4-phenyl-5-phenylaminocarbonyloxyeth
ylthiazole.
0.7 g of the alcohol prepared according to Example 16 and 0. 2 ml of phenyl
isocyanate are stirred overnight at room temperature in 5 ml of
dichloromethane. The precipitate formed is separated by filtration and
then purified by chromatography on a silica gel, eluent:
dichloromethane/ethyl acetate 95/5 (v/v).
m=0.52 g
m.p.=156.degree. C.
B) Compound 52
0.5 g of the compound prepared above is dissolved in 30 ml of ethanol and 5
ml of water and then 0.21 g of Na.sub.2 CO.sub.3 is added.
The reaction mixture is stirred overnight at room temperature and then
concentrated under vacuum. The residue is taken up in ethyl acetate and
washed successively with a solution of Na.sub.2 CO.sub.3 and with water.
The organic phase is separated by decantation and concentrated under
vacuum. The residue is taken up in ether.
m=0.4 g
m.p.=249.degree. C.
EXAMPLE 53
2-[(2-Indolyl)carbonylamino]-4,5-dihydro-[5,4-d]-1H-thiazolobenzoxepin
##STR101##
1 g of the thiazole prepared above (Preparation F), 2.6 g of BOP, 0.93 g of
1-acetylindole-2-carboxylic acid and 0.46 g of triethylamine are mixed in
30 ml of dimethylformamide. The reaction mixture is stirred for 30 hours
at room temperature. The dimethylformamide is evaporated, and the residue
is taken up in ethyl acetate and washed with water. The organic phase is
dried over sodium sulphate and evaporated. The residue is chromatographed
on a silica gel, eluent: dichloromethane/methanol 100+0.5 (v/v). 0.9 g of
a yellow foam is obtained and it is solubilised in dichloromethane to
which ethanol (100 ml) has been added. 10 ml of 2N NAOH are added and the
mixture is stirred at room temperature for 1 hour. After evaporation of
the organic solvents, the residue is taken up in ethyl acetate and washed
with a buffer solution, pH=2. The organic phase is dried over MgSO.sub.4,
filtered and evaporated. Yellow crystals are obtained which are then
washed with dichloromethane and then with ethanol.
m=0.45 g
m.p.>260.degree. C.
EXAMPLE 54
2-[(2-Indolyl)carbonylamino]-4-phenyl-5-(1-piperidinyl)thiazole.
##STR102##
A) 2-Amino-4-phenyl-5-(1-piperidinyl)thiazole.
A mixture of 1 g of 2-amino-4-phenyl-5-bromothiazole and 1.7 g of
piperidine in 25 ml of absolute ethanol is refluxed for 48 hours. The
ethanol is concentrated under vacuum and the residue is taken up in 50 ml
of water and 10 ml of 30% NAOH. It is extracted with ethyl acetate, and
the organic phase is dried over Na.sub.2 CO.sub.4 and filtered. The
solution is concentrated under vacuum and the residue is recrystallised
from isopropyl ether.
m=0.41 g
m.p=135.degree.-137.degree. C.
B) Compound 54
0.4 g of the product obtained above is dissolved in 50 ml of
dichloromethane. 0.33 g of 1-acetylindole-2-carboxylic acid, 0.82 g of BOP
and 0.19 g of triethylamine are added successively. The reaction mixture
is stirred for 4 days at room temperature. 25 ml of water are added and
the organic phase is separated by decantation, dried over Na.sub.2
SO.sub.4 and concentrated under vacuum. The residue is taken up in 50 ml
of absolute ethanol, and 10 ml of 2.5N NAOH are added and the mixture is
stirred for 3 hours at room temperature. The mixture is concentrated under
vacuum, and the residue is taken up in 50 ml of water, extracted with
ethyl acetate, and the organic phase is separated by decantation, dried
over Na.sub.2 SO.sub.4 and concentrated under vacuum. The residue is
recrystallised from ethyl acetate.
m=0.26 g
m.p.>260.degree. C.
By carrying out the procedure according to Example 54, the compounds 55 and
56, which are described in Table 9 below, are prepared.
TABLE 9
______________________________________
##STR103##
Example No.
R.sub.V m.p.; .degree.C.
______________________________________
55
##STR104## >300
56
##STR105## 247-249
______________________________________
EXAMPLE 57
2-[(2-Indolyl)carbonylamino]-5-bromo-4-phenylthiazole.
##STR106##
3.9 g (0.015 mole) of 2-amino-5-bromothiazole are dissolved in 60 ml of
dichloromethane.
3.26 g of 1-acetylindole-2-carboxylic acid, 8.1 g of BOP, 1.85 g of
triethylamine are added, and the reaction mixture is stirred at room
temperature for 8 days and then 100 ml of an aqueous solution which is
buffered to pH=2 are added, and the mixture is decanted, and the organic
phase is dried over Na.sub.2 SO.sub.4 and concentrated under vacuum. The
residue is taken up in 100 ml of methanol and then 5 g of Na.sub.2
CO.sub.3 are added. The mixture is stirred for three hours at room
temperature, concentrated under vacuum at low temperature, and taken up in
100 ml of an aqueous solution which is buffered to pH=2, extracted with
ethyl acetate and the organic phase is dried over Na.sub.2 SO.sub.4. The
mixture is filtered and concentrated under vacuum. The residue is
chromatographed on a silica gel, eluent: CH.sub.2 Cl.sub.2. After removing
the top impurities, the expected product is eluted, and it is
recrystallised, after evaporation of the solvent, from a CH.sub.2 Cl.sub.2
/diisopropyl ether mixture.
m=2.8 g
m.p.=224.degree.-226.degree. C.
EXAMPLE 58
2-[(2-Indolyl)carbonylamino]-5-methoxy-4-phenylthiazole
##STR107##
3.15 g of 2-amino-5-methoxy-4-phenylthiazole are dissolved in 60 ml of
CH.sub.2 Cl.sub.2. 3.26 g of 1-acetylindole-2-carboxylic acid, 8.12 g of
BOP and 1.86 g of triethylamine are added, and the reaction mixture is
stirred at room temperature for one week. 50 ml of water are added and the
organic phase is decanted, dried over Na.sub.2 SO.sub.4, filtered and
concentrated under vacuum. The residue is taken up in 100 ml of methanol,
and 10 g of K.sub.2 CO.sub.3 are added and the mixture is stirred
overnight at room temperature. The mixture is concentrated under vacuum,
and the residue is taken up in water, and the precipitate formed is
separated by filtration and washed with CH.sub.2 Cl.sub.2.
m=1.7 g
m.p.>260.degree. C.
By carrying out the procedure according to the example above, the compounds
59 to 61, which are described in Table 10 below, are prepared.
TABLE 10
______________________________________
##STR108##
Example No. r.sub.4 m.p.; .degree.C.
______________________________________
59 2-Cl 260-262
60 4-CH.sub.3
252-254
61 2-OCH.sub.3
248-250
______________________________________
EXAMPLE 62
2-[(2-Indolyl)carbonylamino]-5-hydroxy-4-phenylthiazole
##STR109##
0.58 g of the thiazole prepared according to Example 58 are dissolved in
100 ml of CH.sub.2 Cl.sub.2. 4.98 ml of a 2M solution of boron tribromide
in CH.sub.2 Cl.sub.2 are added at room temperature and the reaction
mixture is left stirring for 24 hours. 4.98 ml of BBr.sub.3 are again
added, the mixture left for 5 days at room temperature and 4.98 g of
BBr.sub.3 are finally added and the reaction mixture is left at room
temperature for 48 hours. It is then adjusted to pH=5-6 by the addition of
a 4N solution of NaOH and then the organic phase is extacted with 2 times
50 ml of 4N NAOH. The aqueous phase is neutralised by adding a 2N solution
of HC1. The mixture is extracted with CH.sub.2 Cl.sub.2, and the organic
phases are dried over Na.sub.2 SO.sub.4, filtered and concentrated under
vacuum to produce a residue which crystallises.
m=0.5 g
m.p.=237.degree.-239.degree. C.
Top